在双主动脉疾病中进行过导管主动脉植入 (TAVI):系统性审查
Christopher J Goulden1, Kelly Wright2, Samina Alim3
1From the Liverpool University Hospitals Foundation Trust, Liverpool, United Kingdom.
Cardiology in review
|September 5, 2024
概括
通过导管的大动脉植入 (TAVI) 为双管大动脉 (BAV) 疾病患者提供了好处,改善了血液动力学. 然而,中度并发症和1年死亡率显著上升需要仔细选择和监测患者.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 心脏外科手术 心脏外科手术
背景情况:
- 双主动脉 (BAV) 疾病对过导管主动脉植入 (TAVI) 提出了独特的挑战.
- 与三主动脉相比,在BAV患者中TAVI的结果仍然不太清楚.
研究的目的:
- 综合评估TAVI在双上大动脉疾病患者的临床和程序结果.
- 为了评估血液动力学改善,手术成功率,并发症概况和与TAVI相关的死亡率在这个特定的患者队列中.
主要方法:
- 在PubMed,Medline和谷歌学者中进行了系统的文献搜索,直到2023年11月.
- 分析了29项涉及8045名BAV患者的研究数据,重点关注临床,程序和心声学结果.
- 统计分析包括描述性统计,子组分析和敏感性分析,以确定重大发现.
主要成果:
- 在BAV患者中,TAVI显著改善了血液动力学,减少了平均大动脉梯度并增加了大动脉膜面积.
- 实现了93.3%的高程序成功率,主要是通过大腿部接入,但需要起器 (12.6%) 和急性损伤等并发症也被注意到.
- 虽然术后死亡率很低 (3.7%),但所有原因死亡率在1年后显著上升至16.8%.
结论:
- 透导管大动脉植入证明了双管大动脉病患者手术前期的良好结果和血液动力学益处.
- 中度的并发症率和1年死亡率的大幅增加凸显了对细致的患者选择和严格的术后护理的迫切需要.
- 进一步的研究对于阐明长期结果和优化TAVI程序对于BAV群体至关重要.
更多相关视频
09:57Four-Dimensional Computed Tomography-Guided Valve Sizing for Transcatheter Pulmonary Valve Replacement
Published on: January 20, 2022
2.6K
05:31Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
Published on: June 8, 2022
2.8K
相关概念视频
Mitral Valve Prolapse II: Assessment and Management
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Regurgitation III: Medical Management
Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
Mitral Stenosis III: Medical Management
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
